USA flag logo/image

An Official Website of the United States Government

Nitric Oxide-Releasing Wound Dressing for Preventing Chronic Wound Infections

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88693
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI074098
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
NOVAN, INC.
4222 Emperor Blvd, Suite 470 Durham, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Nitric Oxide-Releasing Wound Dressing for Preventing Chronic Wound Infections
Agency: HHS
Contract: 2R44AI074098-03
Award Amount: $2,732,739.00
 

Abstract:

DESCRIPTION (provided by applicant): Many wounds, such as surgical and traumatic injuries, heal without difficulty. Chronic wounds, however, typically exhibit delayed healing in patients with underlying medical conditions that prevent normal tissue repair. For example, approximately 15% of all people with diabetes mellitus will develop a foot ulcer at some point in their lives. Diabetic foot ulcers have an increased risk of infection due to the slow healing times caused by poor blood circulation in the extr emities and other associated co-morbidities. The treatment of diabetic foot ulcers is further complicated by the presence of multidrug resistant pathogens like MRSA methicillin resistant Staphylococcus aureus) and Pseudomonas aeruginosa. If left untreated, contaminated foot ulcers routinely become clinically infected and may ultimately lead to lower-limb amputations. This Phase II aims to develop a topical wound dressing that functions safely and effectively to prevent these and other chronic wound infectio ns. Novan, Inc. was founded to commercialize an innovative platform technology that harnesses the anti-infective power of nitric oxide (NO). During Phase I, Novan successfully created polyurethane films containing nitric oxide-loaded precipitated silica (Nitricil(tm)) that exhibit broad spectrum efficacy against Gram-negative and Gram-positive bacteria, including P. aeruginosa. Following extensive discussions with clinicians and a thorough assessment of advanced wound care products utilized to manage inf ection, the goal of this three17 year project is to manufacture an absorbent nitric oxide-releasing wound dressing called Nitrisorb(tm). The specific aims for this project are to 1) optimize the dose of Nitricil(tm)-loaded in the wound contact layer, 2) pr oduce commercially viable wound dressing prototypes, and 3) evaluate Nitrisorb(tm) product performance and safety in vivo. The Nitrisorb(tm) product could lead to a significant reduction in the costs of chronic wounds by improving the healing time, reducin g the number of hospital days, and decreasing the number of procedures required to treat infections. The only FDA approved use of NO is as a drug in the gaseous form to treat pulmonary hypertension in neonates (INOmax, 1999). The unprecedented use of NO in a wound dressing dictates the submission of a Request for Designation (RFD) to the FDA's Office of Combination Products. A formal response will designate the regulatory jurisdiction and path required to obtain product approval (i.e., drug, device, or b iologic). Ultimately, Novan aspires to commercialize the first NO-based wound dressing. The Company has assembled a strong team of scientists, clinicians, contractors, and business leaders who believe in the technology and are positioned to ensure the grea test likelihood for success. PUBLIC HEALTH RELEVANCE: Many wounds, such as surgical and traumatic injuries, heal without difficulty. Chronic wounds, however, typically exhibit delayed healing in patients with underlying medical conditions that preve nt normal tissue repair. For example, approximately 15% of all people with diabetes mellitus will develop a foot ulcer at some point in their lives. If left untreated, contaminated foot ulcers routinely become clinically infected and may ultimately lead to lower-limb amputations. The goal of this Phase II project is to develop an absorbent nitric oxide-releasing wound dressing (Nitrisorb ) that functions safely and effectively to prevent these and other chronic wound infections.

Principal Investigator:

Nathan A. Stasko
9194149606
STASKO@NOVANONLINE.COM

Business Contact:

Cari Green
cgreen@novanonline.com
Small Business Information at Submission:

NOVAN, INC.
Novan, Inc. PO Box 110023 Research Triangle Park, NC -

EIN/Tax ID: 120442768
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No